KEZAR LIFE SCIENCES INC
Kezar Life Sciences (ticker: KZR) is a small-cap clinical-stage biotechnology company focused on selective immunoproteasome inhibition to treat autoimmune and inflammatory diseases. Its lead candidate has been studied in conditions such as lupus and inflammatory myopathies, and the company’s progress is driven by clinical trial readouts and regulatory milestones. With a market capitalisation around $45.6m, Kezar is research-heavy and has limited commercial revenue; its valuation largely reflects future clinical outcomes and potential partnerships. Investors should be aware that biotech equities at this stage can be volatile and binary in nature — trial results, safety data, financing events or regulatory decisions can move the share price sharply. This summary is for educational purposes only and not personal investment advice; investors should consider their risk tolerance, seek professional advice if needed, and review Kezar’s regulatory filings and public disclosures before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Kezar Life Sciences' stock with a target price of $70.67, indicating potential growth.
Financial Health
Kezar Life Sciences is showing strong cash flow and solid book value, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts and regulatory steps can be material for valuation, though results can be binary and unpredictable.
Novel mechanism focus
Selective immunoproteasome inhibition targets immune pathways differently to some existing therapies; scientific progress matters, and so does safety data.
Funding and dilution
With limited commercial revenue, the company may need further financing which can dilute holders; balance growth potential with this financing risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
